Hayao Nakanishi

Hayao Nakanishi

Auto-generated profile, based on publicly available information

Hayao Nakanishi

Laboratory of Pathology and Clinical Research, Aichi Cancer Center Aichi Hospital, Okazaki 444-0011, Japan

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2012 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
SMS Maseki
S Maseki
KIK Ijichi
K Ijichi
HTH Tanaka
H Tanaka
MFM Fujii
M Fujii
YHY Hasegawa
Y Hasegawa
HNH Nakanishi
H Nakanishi
Epithelial mesenchymal transition (EMT) is known to be associated with chemoresistance as well as increased invasion/metastasis. However, the relationship between EMT and resistance to an epidermal growth factor receptor (EGFR) -targeting drug in head and neck squamous cell carcinoma (HNSCC) remains unknown. In this study, we investigated the acquisition of EMT by gefitinib in HNSCC cell line (UMSCC81B). We isolated fibroblastoid variant (81B-Fb) from gefitinib-resistant UMSCC81B-GR3 cells obtained after increasing the doses of gefitinib treatment in vitro and examined EMT and its underlying mechanism. 81B-Fb cells exhibited fibroblast-like morphology, increased motility, loss of E-cadherin, acquisition of vimentin and snail expression. In 81B-Fb cells, downregulation of EGFR, which is mediated by increased ubiquitination, and activation of downstream protein kinase B (Akt), glycogen synthase kinase-beta (GSK-3β) signalling and upregulation of snail expression were observed compared with UMSCC81B cells. LY294002, but not U0126, suppressed foetal bovine serum or heregulin-β1-induced phosphorylation of Akt/GSK-3β and snail expression together with the inhibition of 81B-Fb cell motility. Furthermore, forced expression of EGFR resulted in partial restoration of gefitinib sensitivity and reversal of EMT. These results suggest that EMT in the gefitinib-resistant cells is mediated by the downregulation of EGFR and compensatory activation of Akt/GSK-3β/snail pathway.

11 February 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AYAkiko Yusa
Akiko Yusa
MTMakoto Toneri
Makoto Toneri
TMTaisuke Masuda
Taisuke Masuda
SISeiji Ito
Seiji Ito
SYShuhei Yamamoto
Shuhei Yamamoto
HNHayao Nakanishi
Hayao Nakanishi
Circulating tumor cells (CTCs) in the blood of patients with epithelial malignancies provide a promising and minimally invasive source for early detection of metastasis, monitoring of therapeutic effects and basic research addressing the mechanism of metastasis. In this study, we developed a new filtration-based, sensitive CTC isolation device. This device consists of a 3-dimensional (3D) palladium (Pd) filter with an 8 µm-sized pore in the lower layer and a 30 µm-sized pocket in the upper layer to trap CTCs on a filter micro-fabricated by precise lithography plus electroforming process. This is a simple pump-less device driven by gravity flow and can enrich CTCs from whole blood within 20 min. After on-device staining of CTCs for 30 min, the filter cassette was removed from the device, fixed in a cassette holder and set up on the upright fluorescence microscope. Enumeration and isolation of CTCs for subsequent genetic analysis from the beginning were completed within 1.5 hr and 2 hr, respectively. Cell spike experiments demonstrated that the recovery rate of tumor cells from blood by this Pd filter device was more than 85%. Single living tumor cells were efficiently isolated from these spiked tumor cells by a micromanipulator, and KRAS mutation, HER2 gene amplification and overexpression, for example, were successfully detected from such isolated single tumor cells. Sequential analysis of blood from mice bearing metastasis revealed that CTC increased with progression of metastasis. Furthermore, a significant increase in the number of CTCs from the blood of patients with metastatic breast cancer was observed compared with patients without metastasis and healthy volunteers. These results suggest that this new 3D Pd filter-based device would be a useful tool for the rapid, cost effective and sensitive detection, enumeration, isolation and genetic analysis of CTCs from peripheral blood in both preclinical and clinical settings.

1 January 2004 in Clinical & Experimental Metastasis
Verified
Journal Article
Closed access
PDF file
YMYoshinari Mochizuki
Yoshinari Mochizuki
HNHayao Nakanishi
Hayao Nakanishi
YKYasuhiro Kodera
Yasuhiro Kodera
SISeiji Ito
Seiji Ito
YYYoshitaka Yamamura
Yoshitaka Yamamura
MTMasae Tatematsu
Masae Tatematsu

14 June 2010 in Cancer Science
Verified
Journal Article
Closed access
PDF file
MMMakoto Matsui
Makoto Matsui
YSYoshitaka Shimizu
Yoshitaka Shimizu
YKYasuhiro Kodera
Yasuhiro Kodera
EKEisaku Kondo
Eisaku Kondo
YIYuzuru Ikehara
Yuzuru Ikehara
HNHayao Nakanishi
Hayao Nakanishi

7 November 2006 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
HYH Yokoyama
H Yokoyama
YIY Ikehara
Y Ikehara
YKY Kodera
Y Kodera
SIS Ikehara
S Ikehara
YYY Yatabe
Y Yatabe
HNH Nakanishi
H Nakanishi
Gastric cancer metastasised to the liver was found to overexpress HER2 at a significantly higher incidence than primary gastric cancers. The purpose of the present study was to investigate the possibility of molecular therapy targeting HER2 overexpression in gastric cancer liver metastasis. We developed three new HER2-overexpressing gastric cancer cell lines (GLM-1, GLM-2, GLM-4) without epidermal growth factor receptor (EGFR) mutations derived from such liver metastasis, two of which had HER2 gene amplifications. All these GLM series of cell lines were highly sensitive to gefitinib in vitro, a specific inhibitor of EGFR tyrosine kinase (Iressa) rather than anti-HER2 antibody trastuzumab (Herceptin), whereas most of the HER2 low-expressing counterparts were not. In these HER2-overexpressing GLM series, protein kinase B (Akt), but not extracellular signal-regulated kinase 1/2 (ERK1/2), was constitutively phosphorylated, and gefitinib efficiently inhibited this Akt phosphorylation, induced strong apoptosis in vitro and exhibited antitumour activity in tumour xenografts in nude mice. This gefitinib-mediated antitumour effect in xenograft was significantly potentiated by trastuzumab treatment. On the other hand, gefitinib-resistant cells (GLM-1R) exhibited increased EGFR expression, followed by constitutive activation of mitogen-activated protein kinase (MAPK) pathway. These results suggest that the antitumour effect of gefitinib is due to the effective inhibition of HER2-driven constitutive activation of phosphatidylinositol-3-kinase (PI3K)/Akt pathway, and that the acquired resistance to gefitinib is due to the constitutive activation of Ras/MAPK pathway in compensation for PI3K/Akt pathway. Gastric cancer liver metastasis with HER2 overexpression would be a potential molecular target for gefitinib and trastuzumab.

16 April 2008 in Cancer Science
Verified
Journal Article
Open access
PDF file
MHMasayasu Hara
Masayasu Hara
HNHayao Nakanishi
Hayao Nakanishi
KTKunio Tsujimura
Kunio Tsujimura
MMMakoto Matsui
Makoto Matsui
YYYasushi Yatabe
Yasushi Yatabe
MTMasae Tatematsu
Masae Tatematsu
Cetuximab, a chimeric monoclonal antibody to epidermal growth factor receptor (EGFR), has been proved to have clinically significant antitumor activity against advanced colorectal cancers, but its therapeutic activity for gastric cancers remains unclear. In the present study, we investigated the antitumor effect and action mechanism of cetuximab using EGFR high‐expressing (MKN‐28) and EGFR low‐expressing (GLM‐1) gastric cancer cell lines without gene amplification. Cetuximab showed neither significant growth inhibition nor induction of apoptosis in either cell line in vitro, and only slightly inhibited ligand‐induced phosphorylation of protein kinase B and extracellular signal‐regulated kinase in MKN‐28 cells. In contrast, cetuximab significantly inhibited subcutaneous and intraperitoneal tumor growth of MKN‐28 cells, but not GLM‐1 cells, in nude mice. This antitumor activity was significantly enhanced and diminished in nude mice by treatment with interleukin‐2 (IL‐2) and antiasialo GM1 antibody, which can expand and deplete natural killer (NK) cells, respectively. Antibody‐dependent cellular cytotoxicity (ADCC) of cetuximab, as measured by 51Cr release assay, was significantly higher in MKN‐28 than in GLM‐1 cells. This ADCC activity was enhanced by IL‐2 and reduced by heat‐aggregate of human immunoglobulin G, an inhibitor for FcR‐III of NK cells. These results suggest that cetuximab in combination with IL‐2 shows significant antitumor activity against EGFR high‐expressing gastric cancer mainly through NK cell‐mediated ADCC. Combination therapy with cetuximab and IL‐2 would thus offer a new potential therapeutic approach for a subset of EGFR‐overexpressing gastric cancers. (Cancer Sci 2008; 99: 1471–1478)